Structure via PubChem · Public domain (PubChem)
pegaptanib
Sign in to saveAlso known as Pegaptanib Octasodium, NX1838, Pegaptanib sodium, EYE 001, NX 1838
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
Chemical data
- Formula
- C20H40N3NaO10P
- Molecular weight
- 536.5 g/mol
- SMILES
- COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- InChIKey
- HZXSQIHZPVCLDJ-LMOVPXPDSA-N
- Polar surface area
- 171 Ų
- H-bond donors
- 4
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2004
- Admin. routes
- parenteral
- Indications
- age-related macular degeneration, retinal vein occlusion, macular degeneration, wet macular degeneration
via ChEMBL · EBI
Research
688 papers- Pegaptanib.2006
- Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.Clinical therapeutics · 2006
- Pegaptanib sodium.Nature reviews. Drug discovery · 2005
- Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.The British journal of ophthalmology · 2007
- Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.Expert opinion on pharmacotherapy · 2005
via PubMed
Wikidata facts
- Mass
- 536.2349
- Has use
- medication
Show 5 more facts
- chemical formula
- C₂₀H₄₀N₃NaO₁₀P
- canonical SMILES
- COCCOC(=O)NCCCCC(C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- NCI Thesaurus ID
- C90657
- isomeric SMILES
- COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- has characteristic
- biopharmaceutical
Sources (2)
via Wikidata · CC0
~7 min read
Encyclopedic overview
12 sectionsContents
- Mechanism of action
- Means of administration
- Preclinical trials
- Animal toxicology studies
- Clinical studies
- Phase I
- Phase II
- Phase III
- Regulatory approval information
- Side effects
- Commercialization
- References
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
==Mechanism of action== Pegaptanib is a pegylated anti-vascular endothelial growth factor (VEGF) aptamer, a single strand of nucleic acid that binds with specificity to a particular target. Pegaptanib specifically binds to the 165 isoform of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular AMD.
Excerpted from Wikipedia’s “pegaptanib” article, available under the CC BY-SA 4.0 licence.